73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Vivani Medical
Open
1.29 4.88
Overview
Share price change
24h
Min
1.24
Max
1.33
Employees | 37 |
|---|
Recommendations | Buy |
|---|---|
12 Months Forecast | +238.98% upside |
Next Earnings | 30 Mar 2026 |
|---|
Market Cap | -20M 84M |
|---|---|
Previous open | -3.59 |
Previous close | 1.29 |
Vivani Medical Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vivani Medical Forecast
Price Target
By TipRanks
238.98% upside
12 Months Forecast
Average 4 USD 238.98%
High 4 USD
Low 4 USD
Based on 1 Wall Street analysts offering 12 month price targets forVivani Medical - Dist in the last 3 months.
Financials
$
About Vivani Medical
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
Live chat